Ethical issues in psychopharmacology.

California State University, Northridge, Department of Philosophy, 18111 Nordhoff Street, Northridge, California 91330-8253, USA.
Journal of Medical Ethics (Impact Factor: 1.69). 08/2006; 32(7):405-10. DOI: 10.1136/jme.2005.013185
Source: PubMed

ABSTRACT The marketing of selective serotonin reuptake inhibitors in the psychopharmacological industry presents a serious moral problem for the corporate model of medicine. In this paper I examine ethical issues relating to the efficacy and safety of these drugs. Pharmaceutical companies have a moral obligation to disclose all information in their possession bearing on the true risks and benefits of their drugs. Only then can patients make fully informed decisions about their treatment.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This essay examines the effects of commercialization on education with particular focus on corporatization of academic research. This trend results from a business model of education, which I identify as profit‐based inquiry. I contrast profit‐based inquiry with Nicholas Maxwell's conception of wisdom‐based inquiry and conclude that the business model fails to achieve enduring value and results in a promotional or ideological emphasis rather than one that stresses the importance of critical rationalism. In order to make my case for this failure, I focus attention on the current state of commercialization in research of medicines.
    London Review of Education 07/2007; 5(2):131-142. DOI:10.1080/14748460701440665
  • Source
    Postgraduate medical journal 04/2010; 86(1014):193-6. DOI:10.1136/hrt.2009.186957 · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psychopharmacology is a powerful tool in psychiatry; however, it is one that demands responsibility in order to deal with the ethical complexities that accompany advances in the field. It is important that questions are asked and that ethical mindfulness and sensitivity are developed along with clinical skills. In order to cultivate and deepen ethical awareness and subsequently solve issues in optimal fashion, investment should be made in the development of an ethical decision-making process as well as in education in the ethics of psychopharmacology to trainees in the field at all stages of their educational development. A clear approach to identifying ethical problems, engaging various ethical concepts in considering solutions and then applying these principles in problem resolution is demanded. An openness in identifying and exploring issues has become crucial to the future development and maturation of psychopharmacologists, both research and clinical. Consideration must be given to the social implications of psychopharmacological practice, with the best interests of patients always paramount. From both a research and clinical perspective, psychopharmacology has to be practised with fairness, sensitivity and ethical relevance to all. While ethical issues related to psychopharmacological practice are varied and plentiful, this review focuses on advances in technology and biological sciences, personal integrity, special populations, and education and training.
    The International Journal of Neuropsychopharmacology 04/2011; 14(3):413-24. DOI:10.1017/S1461145710001112 · 5.26 Impact Factor


Available from